Louisiana 2018 Regular Session

Louisiana House Bill HCR19

Introduced
3/26/18  
Introduced
3/26/18  
Refer
3/27/18  
Refer
3/27/18  
Report Pass
4/4/18  
Engrossed
4/9/18  
Refer
4/10/18  
Refer
4/10/18  
Report Pass
5/2/18  
Report Pass
5/2/18  

Caption

Requests the La. Department of Health to add Severe Combined Immunodeficiency to the state's newborn screening panel

Impact

If enacted, HCR19 would align Louisiana's newborn screening protocols with those of forty-six other states, enhancing the state's ability to identify and manage life-threatening genetic conditions early. The addition of SCID to the screening panel would potentially improve health outcomes for infants born with this disorder by facilitating timely diagnosis and treatment before severe complications arise. This change would reflect a commitment to improving public health and safeguarding newborns' health across Louisiana.

Summary

House Concurrent Resolution 19 (HCR19) requests the Louisiana Department of Health to add Severe Combined Immunodeficiency (SCID) to the state's newborn screening panel. SCID is a life-threatening condition that severely impairs the immune system, making those affected extremely vulnerable to infections. The resolution underscores the importance of early detection through newborn screening to ensure timely intervention and treatment, which could be critical for survival. Currently, Louisiana does not include SCID in its screening panel, while the majority of other states already do.

Sentiment

The sentiment surrounding HCR19 appears to be positive, with broad support for the initiative to improve infant health through expanded screening. The resolution has likely gained bipartisan backing, as it emphasizes a health care concern that transcends political lines—the welfare of newborns. Advocates for newborn health and genetic disorder awareness have likely played a crucial role in promoting the importance of this resolution, highlighting the need for Louisiana to enhance its public health framework.

Contention

While there seems to be consensus on the necessity of adding SCID to the screening panel, potential contention may arise around funding and the implementation logistics of introducing new tests into the existing screening process. Concerns may include the costs affiliated with expanded testing and ensuring that healthcare providers are trained appropriately to address the increased workload and reporting obligations. However, the potential benefits to infant health and mortality rates could outweigh these challenges, making it a topic worth pursuing.

Companion Bills

No companion bills found.

Previously Filed As

LA SCR16

Requests the La. Department of Health to add Spinal Muscular Atrophy (SMA) to the state's newborn screening panel.

LA HCR33

Requests a study concerning potential inclusion in the state's newborn screening panel of all disorders listed on the federal Recommended Uniform Screening Panel

LA HCR34

Provides for the potential addition of mucopolysaccharidosis type I and Pompe disease to the state's newborn screening panel

LA SCR3

Requests the Department of Health and Hospitals to submit a report by October 1, 2016, and to add Adrenoleukodystrophy (ALD) to the newborn screening panel no later than August 1, 2017.

LA SB00543

An Act Providing Newborn Screening For Severe Combined Immunodeficiency Disease.

LA AB2563

Newborn screening program.

LA HCR69

Requests a study concerning means by which to improve the Medicaid estate recovery functions of the La. Department of Health

LA HCR111

Requests the La. Department of Health to require all Medicaid managed care plans to participate in the quality incentive program

LA HCR76

Urges and requests the La. Department of Health to convene an opioid action summit

LA SCR17

Directs the Department of Health and Hospitals to evaluate and report on the health benefits and costs of adding Krabbe disease to the list of mandatory screenings performed on newborns under certain circumstances.

Similar Bills

No similar bills found.